Clinical-stage biotechnology company Bambusa Therapeutics Inc announced on Tuesday that the first patient has been dosed in the Phase Ib clinical trial of BBT002, a novel platform-in-a-molecule bispecific antibody targeting IL-4R alpha and IL-5, in patients with chronic obstructive pulmonary disease (COPD).

The Phase Ib study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BBT002 in COPD, as well as other type 2 inflammatory respiratory indications, including asthma and chronic rhinosinusitis with nasal polyps. The company anticipates initial data in the second half of 2026.

According to Bambusa, BBT002 is designed to simultaneously inhibit IL-4/IL-13 and IL-5 signalling, two central and complementary drivers of type 2 inflammation that together shape disease expression across multiple organ systems and stages of life. By targeting both pathways in a single, long-acting molecule, BBT002 has the potential to deliver broader and more durable suppression of underlying disease biology than existing single-target therapies, offering a unified therapeutic approach across respiratory and other type 2 inflammatory conditions.